Value added medicines: what value repurposed medicines might bring to society?

  title={Value added medicines: what value repurposed medicines might bring to society?},
  author={M. Toumi and C. R{\'e}muzat},
  journal={Journal of Market Access \& Health Policy},
ABSTRACT Background & objectives: Despite the wide interest surrounding drug repurposing, no common terminology has been yet agreed for these products and their full potential value is not always recognised and rewarded, creating a disincentive for further development. The objectives of the present study were to assess from a wide perspective which value drug repurposing might bring to society, but also to identify key obstacles for adoption of these medicines and to discuss policy… Expand
PP120 Health Technology Assessment Framework To Capture The Full Value Of Value Added Medicines
Barriers and facilitators of exploiting the potential of value-added medicines
The Added Value of Liquid Antipsychotics: The Case of Quetiapine
The Mixed-Method 5W2D Approach for Health System Stakeholders Analysis in Quality of Care: An Application to the Moroccan Context


Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases
  • M. Allarakhia
  • Business, Medicine
  • Drug design, development and therapy
  • 2013
Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature
Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products.
  • S. Stegemann, I. Klebovich, +8 authors V. Shah
  • Medicine
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2011
Unlicensed and Off-Label Drug Use in Children Before and After Pediatric Governmental Initiatives.
Adherence to Long-Term Therapies: Evidence for Action
  • S. De Geest, E. Sabaté
  • Medicine
  • European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology
  • 2003
The drug budget silo mentality in Europe: an overview.
  • L. Garrison, A. Towse
  • Business, Medicine
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2003